(19)
(11)EP 4 248 751 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
01.11.2023 Bulletin 2023/44

(43)Date of publication A2:
27.09.2023 Bulletin 2023/39

(21)Application number: 22188897.7

(22)Date of filing:  24.01.2005
(27)Previously filed application:
 24.01.2005 PCT/US2005/002273
(51)International Patent Classification (IPC): 
C12N 5/00(2006.01)
(52)Cooperative Patent Classification (CPC):
A61K 35/12; A61K 35/44; C12N 5/0621; C12N 2501/01; C12N 2501/115; C12N 2501/15; C12N 2501/155; C12N 2501/33; C12N 2506/02; A61P 25/16; A61P 27/00; A61P 27/02; A61P 43/00; A61P 9/10; A61P 9/14
(84)Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR LV MK YU

(30)Priority: 23.01.2004 US 53896404 P

(60)Divisional application:
23176537.1 / 4269561
23176538.9 / 4248752

(71)Applicant: President and Fellows of Harvard College
Cambridge, MA 02138 (US)

(72)Inventor:
  • KLIMANSKAYA, Irina
    Upton MA 01568 (US)

(74)Representative: Finnegan Europe LLP 
1 London Bridge
London SE1 9BG
London SE1 9BG (GB)

 
Remarks:
This application was filed on 04-08-2022 as a new European patent application according to Article 61(1)(b) EPC in respect of the original application 05711960.4.
 


(54)IMPROVED MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA


(57) This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.





Search report












Search report